Rail Vikas Nigam Q2 Results: Net Profit Drops 27% to ₹287 Crore, Falling Short of Estimates
Lupin Q2 Results: Net Profit Surges 74% to ₹853 Crore, Revenue Climbs 13%
Last Updated: 8th November 2024 - 09:39 am
Mumbai-based pharmaceutical company Lupin Ltd announced a 74.1% year-on-year increase in consolidated net profit, reaching ₹852.63 crore for the July-September quarter of FY25, surpassing analysts' expectations. The company's revenue rose to ₹5,672.73 crore, a 12.6% increase from ₹5,038.56 crore in the same quarter last year.
Lupin Quarter Results Highlights
• Revenue: ₹5,672.73 crore, marking a 12.6% increase compared to ₹5,038.56 crore in the same quarter last year.
• Net Profit: ₹852.63 crore, a 74.1% increase year-on-year.
• EBITDA: ₹1,340.3 crore, reflecting a 46% increase, with an EBITDA margin of 23.6%.
Stock Market Reaction after Lupin Quarter Results
Lupin shares closed at ₹2,104.85 per share on the NSE on Thursday evening.
About Lupin
Lupin Ltd, headquartered in Mumbai, Maharashtra, specializes in developing and manufacturing both generic and branded formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company has strong expertise in therapeutic areas such as cardiovascular health, asthma, diabetes management, pediatrics, central nervous system disorders, gastrointestinal issues, anti-infectives, NSAIDs, anti-tuberculosis, and cephalosporins. Lupin is deeply invested in research and development, focusing on pharmaceuticals for conditions like migraines, gastrointestinal disorders, psoriasis, central nervous system diseases, cardiovascular issues, tuberculosis, diabetes, and inflammation. Additionally, it develops enhanced generic drugs utilizing its proprietary platform technologies. Together with its subsidiaries, Lupin operates manufacturing facilities across India, the U.S., Mexico, and Brazil.
Trending on 5paisa
06
5paisa Research Team
Discover more of what matters to you.
Corporate Actions Related Articles
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.